Amy D Quigley

US Patent:

20120010193, Jan 12, 2012

Filed:

Mar 8, 2010

Appl. No.:

13/256354

Inventors:

Craig A. Stump - Pottstown PA, US
Amy G. Quigley - Elkins Park PA, US
Cory R. Theberge - Brunswick ME, US
Michael R. Wood - Brentwood TN, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/435
C07D 471/10
C07D 491/107
C07D 498/20
A61K 31/4375
A61P 25/06
A61K 31/536
A61K 31/537
A61K 31/551
A61K 31/553
A61K 31/5377
C07D 471/20
A61K 31/496

US Classification:

51421021, 546 15, 544230, 544 70, 546 16, 544 71, 540575, 540552, 514278, 51425303, 5142305, 514218, 51421109, 5142345

Abstract:

Compounds of Formula (I) (wherein variables A, A, A, ring-B, m, n, J, E, E, E, R, RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.

US Patent:

20140275017, Sep 18, 2014

Filed:

Jun 3, 2014

Appl. No.:

14/294310

Inventors:

Craig A. Stump - Pottstown PA, US
Amy G. Quigley - Elkins Park PA, US
Cory R. Theberge - Brunswick ME, US
Michael R. Wood - Brentwood TN, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/20
C07D 471/10
C07D 519/00

US Classification:

51421018, 51421021, 51421109, 51421202, 514218, 5142298, 5142305, 5142328, 514249, 51425302, 51425303, 514278, 540543, 544 70, 544 71, 544230, 544231, 546 15, 546 17

Abstract:

Compounds of Formula I:(wherein variables A, A, A, ring-B, m, n, J, E, E, E, R, Rand Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.